EUVIMEDObjevte EUVIMED
Multizentrische StudieRandomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus

Stefan Verheye iD, Bert Ferdinande, Johan Bennett iD, Rodolfo Staico, Seif El-Jack, Pim A L Tonino, Alexandre Abizaid, Ian Buysschaert, Douglas Scott, Madhav Menon, Gerard Wilkins, Dougal McClean and 8 more

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70106 ↗

At a glance

Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2025. Written by Stefan Verheye and 19 co-authors. Institution: Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium. Major MEDLINE topics: Sirolimus, Drug-Eluting Stents, Percutaneous Coronary Intervention, Coronary Artery Disease. 27 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: The study was funded by Elixir Medical..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site‐specific thrombotic risk.

Aims

To assess the feasibility and safety of this novel device against a contemporary drug‐eluting stent.

Methods

This prospective, multicenter randomized (1:1) trial included 202 patients assigned between the device group (DESyne BDS Plus) and the control group (DESyne X2). A subgroup of 58 patients underwent imaging follow‐up at 6 months. The blood pharmacokinetics of Sirolimus and both anticoagulants were assessed in 11 nonrandomized patients.

Results

The primary endpoint, target lesion failure (TLF) at discharge or 3‐day postprocedure, whichever occurred first, was 0.0% (0/98) in the device and 5.0% (5/100) in the control group ( p noninferiority < 0.001). The secondary endpoint, late lumen loss at 6 months, was 0.14 mm [90% CI: 0.06; 0.23] and 0.09 mm [90% CI: 0.01; 0.18] in the device ( n = 28) and control group ( n = 27), respectively ( p noninferiority < 0.001). Through 24 months, stent thrombosis (definite/probable) was 0.0% (0/97) versus 1.0% (1/96) in the control, p = 0.497, and TLF was 2.1% (2/97) versus 11.3% (11/97), p = 0.010, respectively. Optical coherence tomography findings including strut coverage and neointimal hyperplasia thickness/volume were similar between the groups. The pharmacokinetic study indicated median maximum blood concentrations (C max ) of Rivaroxaban and Argatroban of 1.38 ng/mL and 1.99 ng/mL, respectively.

Conclusions

This is the first clinical evidence of the feasibility of site‐specific antithrombotic therapeutic with two anticoagulants and an antiproliferative mTOR inhibitor.

Subjects

MeSH terms (MEDLINE)

SirolimusDrug-Eluting StentsPercutaneous Coronary InterventionCoronary Artery DiseaseCardiovascular AgentsPipecolic AcidsRivaroxabanCoronary ThrombosisFactor Xa InhibitorsFibrinolytic AgentsHumansMaleFemaleProspective StudiesTreatment OutcomeMiddle AgedAgedTime FactorsFeasibility StudiesProsthesis DesignSulfonamidesArginineTomography, Optical CoherenceDrug Therapy, CombinationRisk FactorsCoronary Angiography

Author keywords

anticoagulantdrug‐eluting stentstent thrombosis

Substances

SirolimusCardiovascular AgentsargatrobanSulfonamidesPipecolic AcidsRivaroxabanArginineFactor Xa InhibitorsFibrinolytic Agents

Authors and institutions

  • Interventional Cardiology, ZAS Cardiovascular Center Middelheim, Antwerp, Belgium.
  • Department of Cardiology, Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk, Belgium.
  • Department of Cardiovascular Medicine, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
  • Instituto Dante Pazzanese, São Paulo, Brazil.
  • Cardiovascular Unit, North Shore Hospital, Auckland, New Zealand.
  • Heart Center, Catharina Hospital, Eindhoven, the Netherlands.

ORCID profiles: Stefan Verheye, Johan Bennett, Mark Webster

Funding

  • The study was funded by Elixir Medical.

Cite

APA

Verheye, S., Ferdinande, B., Bennett, J., Staico, R., El-Jack, S., Tonino, P. A. L., Abizaid, A., Buysschaert, I., Scott, D., Menon, M., Wilkins, G., McClean, D., Kovarnik, T., Christians, U., Neylon, A., Mehmedbegovic, Z., Smits, P. C., Morice, M. C., Webster, M., & DESyne BDS Plus RCT Investigators (2025). Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70106

Vancouver

Verheye S, Ferdinande B, Bennett J, Staico R, El-Jack S, Tonino PAL, et al. Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70106

BibTeX
@article{Verheye2025,
  author = {Verheye, Stefan and Ferdinande, Bert and Bennett, Johan and Staico, Rodolfo and El-Jack, Seif and Tonino, Pim A L and Abizaid, Alexandre and Buysschaert, Ian and Scott, Douglas and Menon, Madhav and Wilkins, Gerard and McClean, Dougal and Kovarnik, Tomas and Christians, Uwe and Neylon, Antoinette and Mehmedbegovic, Zlatko and Smits, Pieter C and Morice, Marie-Claude and Webster, Mark and DESyne BDS Plus RCT Investigators, DESyne BDS Plus RCT Investigators},
  title = {Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70106}
}
Start for free →